Warfarin

affected my aesthetic knowledge. Having no pervious experience with the side effects of blood thinners except what I learnt from my pharmacology class led me to be incapable at the time to correlate the blood shot eye as a negative effect caused by warfarin. If I had this knowledge, I would have been able to explain to this patient why the bloodshot eye had occurred and I am certain that it would have brought him some reassurance and comfort. The LPN in this scenario implemented aesthetic…

Sialodenitis (Parotitis) Parotitis, or sialadenitis, is an inflammatory reaction of the parotid gland caused by bacterial, viral, fungal, or mycobacterial penetration. The infection originates with retrograde migration of oral cavity flora through Stensen’s duct. Stasis of saliva, ductal obstruction, decreased stimulation of saliva (anorexia), decreased mastication, and poor oral hygiene contribute to retrograde migration. Chronic illnesses, recent surgical procedures, hypovolemia (diarrhea,…

Summary Human Serum albumin (HSA) is a plasma protein in charge of the transportation of the fatty acids (Bhattacharya, Grune & Curry, 2000, p.721). HSA promotes the transportation capacity of plasma because it is currently at around 0.6Mm enabling it to carry more than six molecules of fatty acid. In addition, the HSA binds and agitates the pharmacokinetics of various drugs compounds. The HSA-fatty acid has two drug-binding sites, which are the sub-domains IIA and IIIA. The fatty acid IIIA…

Introduction The clinical connection that I would like to share relates to the patient I was caring for who has a history of actinic keratosis, aortic insufficiency, aortic valve replaced, basal cell carcinoma, clostridium difficile, chronic lymphoid leukemia, erosive esophagitis, GERD, heart failure, hematuria, total hip replacement, hyperlipidemia, hypertension, influenza A, osteoarthritis, iron deficiency, major depressive disorder, MERSA-nares, pressure ulcer of sacral region, squamous cell…

near future a lot of advancement is anticipated. As I write this personal statement, an antidote to Xarelto has passed Phase-3 trials. As it appears, by the end of this year we might have a working antidote to Xarelto, thus retiring the old guard Warfarin. It’s surely an exciting time for all of us and we need to keep ourselves up to speed with this rapidly changing field of modern…

4. Plasminogen Activator Inhibitor-1 (PAI-1) PAI-1 is used to evaluate the risk of thrombosis. It is a serine protease inhibitor (serpin), therefore it is also known as serpin E1. Human SERPINE1 gene encodes for PAI-1. PAI-1 inhibits Fibrinolysis through the inhibition of the serine proteases, Tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), which activate plasminogen. So any increase in PAI-1 decreases fibrinolysis consequently increasing the risk of…

OBJECTIVE: To deliver lornoxicam into systemic circulation by engineering ethosomal gel formulation. RATIONAL OF WORK: Because of their improved pervasion of medication through skin.  lornoxicam is BCS class II medication causes gastric bothering when managed orally  ethosomes are stages for the conveyance of vast and differing gathering of medications.  due to their generally safe profile.  better understanding agreeability can be utilized as a part of the manifestation of gel,…

REASON CHIEF COMPLAINT: Heart failure. Coronary artery disease. Atrial flutter. BLANKLINE This patient had an acute MI _____ and underwent three vessel coronary artery bypass grafting at that time. He states he had a cardiac catheterization elsewhere about four years ago and they did not perform any intervention at that time. He has had a transthoracic echocardiography and stress nuclear imaging test that has shown EF of 40%. His last nuclear imaging test showed only mild inferior…

Nursing Diagnosis: Risk for impaired mobility related to arthritic pain, activity intolerance, and anxiety as evidenced by patient pain score of 5 out of 10 and patient fatigue score of 8 out of 10 on worst days, and patient verbalization of fear of falling. Measureable Outcomes: 1. Arthritis pain reduced to a maximum 2 out of 10 on pain scale 2. Fatigue between transfusions reduced to a maximum 3 out of 10 on pain scale 3. Performs resistance and strength training exercises for 8 muscle…

Lassen et al. (2009) aimed to demonstrate that Apixaban at a dose of 2.5mg twice daily is just as safe and effective as enoxaparin when administered at a dose of 30mg subcutaneously every 12 hours. While Lassen et al. (2010a) observed Apixaban at the same dose but against enoxaparin 40mg once daily. The treatment period for both studies lasted between 10-14 days. The primary efficacy outcome for the above mentioned studies included the following scenarios; symptomatic or non-symptomatic DVT,…